[1]徐怡英.程序性死亡蛋白-1抑制剂治疗晚期非小细胞肺癌的临床疗效及安全性[J].医学信息,2023,36(23):115-117.[doi:10.3969/j.issn.1006-1959.2023.23.029]
　XU Yi-ying.Clinical Efficacy and Safety of Programmed Death Protein-1 Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2023,36(23):115-117.[doi:10.3969/j.issn.1006-1959.2023.23.029]
点击复制

程序性死亡蛋白-1抑制剂治疗晚期非小细胞肺癌的临床疗效及安全性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年23期
页码:
115-117
栏目:
药物与临床
出版日期:
2023-12-01

文章信息/Info

Title:
Clinical Efficacy and Safety of Programmed Death Protein-1 Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer
文章编号:
1006-1959（2023）23-0115-04
作者:
徐怡英
（龙南市第一人民医院肿瘤血液科，江西 龙南 341700）
Author(s):
XU Yi-ying
(Department of Oncology and Hematology,the First People ’s Hospital of Longnan,Longnan 341700,Jiangxi,China)
关键词:
程序性死亡蛋白-1抑制剂; 晚期非小细胞肺癌; 免疫功能; 炎症因子
Keywords:
Programmed death protein-1 inhibitors; Advanced non-small cell lung cancer; Immune function; Inflammatory factors
分类号:
R979.1
DOI:
10.3969/j.issn.1006-1959.2023.23.029
文献标志码:
A
摘要:
目的 观察程序性死亡蛋白-1抑制剂治疗晚期非小细胞肺癌的临床疗效及用药安全。方法 选取2020年1月-2023年5月我院诊治的60例晚期非小细胞肺癌患者为研究对象，采用随机数字表法分为对照组和观察组，各30例。对照组采用常规紫彬醇联合顺铂化疗治疗，观察组在对照组基础上给予程序性死亡蛋白-1抑制剂治疗，比较两组临床疗效、细胞免疫指标（CD3+、CD4+、CD8+）、炎症因子水平[白细胞介素-6（IL-6）、肿瘤坏死因子α（TNF-α）]及不良反应发生率。结果 观察组治疗总有效率为76.67%，高于对照组的46.67%（P＜0.05）；两组治疗后CD3+、CD4+均高于治疗前，CD8+低于治疗前，且观察组CD3+、CD4+高于对照组，CD8+低于对照组（P＜0.05）；两组治疗后IL-6、TNF-α水平均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 晚期非小细胞肺癌采用程序性死亡蛋白-1抑制剂治疗的效果良好，可改善细胞免疫因子和炎症因子水平，且不增加不良反应发生风险。
Abstract:
Objective To observe the clinical efficacy and safety of programmed death protein-1 inhibitor in the treatment of advanced non-small cell lung cancer.Methods A total of 60 patients with advanced non-small cell lung cancer diagnosed and treated in our hospital from January 2020 to May 2023 were selected as the research objects. They were divided into control group and observation group by random number table method, with 30 cases in each group. The control group was treated with conventional violet alcohol combined with cisplatin chemotherapy, and the observation group was treated with programmed death protein-1 inhibitor on the basis of the control group. The clinical efficacy, cellular immune indexes (CD3+, CD4+, CD8+), inflammatory factor levels [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)] and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 76.67%, which was higher than 46.67% in the control group (P<0.05). After treatment, CD3+ and CD4+ in the two groups were higher than those before treatment, CD8+ was lower than that before treatment, and CD3+ and CD4+ in the observation group were higher than those in the control group, CD8+ was lower than that in the control group (P<0.05). After treatment, the levels of IL-6 and TNF-α in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion Programmed death protein-1 inhibitor is effective in the treatment of advanced non-small cell lung cancer, which can improve the levels of cellular immune factors and inflammatory factors without increasing the risk of adverse reactions.

参考文献/References:

[1]黄德良,胡莹.非小细胞肺癌患者血清PD-1基因rs41386349多态性与临床特点相关性[J].广东医学,2020,41(5):496-500.[2]He R,Ding W,Viswanatha DS,et al.PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness[J].Am J Surg Pathol,2018,42(7):843-854.[3]孙璐,王巍,李婵,等.CD14+CD16-HLA-DR+与PD-1单抗治疗非小细胞肺癌的疗效及预后的关系研究[J].国际检验医学杂志,2021,42(8):949-952.[4]刘国强,康朔,王欣晨.帕博利珠单抗一线治疗PD-L1高表达的晚期非小细胞肺癌的药物经济学评价[J].中国药房,2021,32(11):1351-1356.[5]裘飞峰,王凌飞,王喜,等.抗PD-1/PD-L1单抗治疗进展期非小细胞肺癌的效果及对肿瘤浸润T细胞密度及分布的影响[J].实用癌症杂志,2021,36(7):1120-1122.[6]加尔肯古丽·布得汗,王虹,郭志平.阿帕替尼联合吉西他滨和顺铂方案治疗驱动基因阴性非小细胞肺癌的效果[J].中国肿瘤临床与康复,2020,27(4):419-423.[7]王雷,李婧怡,李幸,等.晚期非小细胞肺癌免疫检查点抑制剂治疗专家共识解读[J].河北医科大学学报,2020,41(1):1-6,11.[8]刘一,黄琳,门鹏,等.帕博利珠单抗一线治疗局部晚期/转移性非小细胞肺癌的快速卫生技术评估[J].中国新药杂志,2021,30(12):1137-1146.[9]邱鲁鹏,赵晓,孙胜杰,等.PD-1/PD-L1抑制剂治疗复发小细胞肺癌的真实世界研究[J].临床肿瘤学杂志,2021,26(1):34-41.[10]Sun L,Wang Q,Chen B,et al.Human Gastric Cancer Mesenchymal Stem Cell-Derived IL15 Contributes to Tumor Cell Epithelial-Mesenchymal Transition via Upregulation Tregs Ratio and PD-1 Expression in CD4+T Cell[J].Stem Cells Dev,2018,27(17):1203-1214.[11]陈青,李艳,张文杰,等.多西他赛联合PD-1/PD-L1抑制剂二线治疗晚期非小细胞肺癌的临床分析[J].中国肺癌杂志,2021,24(9):605-612.[12]魏芬芬,相丽,宋耕,等.PD-1单抗引起甲状腺功能异常的发生情况及相关因素研究[J].临床肿瘤学杂志,2020,25(10):930-934.[13]Yoon SM,Shaikh T,Hallman M.Therapeutic management options for stage Ⅲ non-small cell lung cancer[J].World J Clin Oncol,2017,8(1):1-20[14]孙明华.DC-CIK细胞免疫治疗联合化疗对老年中晚期非小细胞肺癌的临床研究[J].国际老年医学杂志,2019,40(6):324-327,340.[15]马成龙,沈冬.程序性死亡受体1抗体联合多西他赛治疗一线化疗进展后晚期非小细胞肺癌的临床观察[J].中国医刊,2019,54(11):1244-1246.[16]Siegel RL,Miller KD,Jemal A.Cancer statistics,2020[J].CA Cancer J Clin,2020,70(1):7-30.[17]林恒,谢强.PD-1抑制剂一线治疗晚期非小细胞肺癌的疗效和安全性[J].中国新药与临床杂志,2021,40(6):436-440.[18]李浩洋,秦娜,俞孟军,等.PD-L1高表达晚期非小细胞肺癌患者单纯免疫治疗与免疫联合化疗疗效比较[J].中国肺癌杂志,2021,24(3):161-166.[19]张华阳,张兴,李仕聪,等.PD-1抑制剂诱发的药物免疫相关不良反应事件的研究[J].中国现代医学杂志,2020,30(17):42-46.[20]江洁美,汪燕燕,王亚露,等.PD-1抑制剂治疗非小细胞肺癌的不良反应分析[J].中国新药与临床杂志,2021,40(6):476-480.

相似文献/References:

[1]朱淑娟.多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的 疗效和安全性评估[J].医学信息,2018,31(15):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
　ZHU Shu-juan.Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(23):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
[2]党升强,崔立春,魏 琳,等.同步放化疗联合扶正肺癌方治疗局部晚期非小细胞肺癌的效果[J].医学信息,2019,32(24):166.[doi:10.3969/j.issn.1006-1959.2019.24.061]
　DANG Sheng-qiang,CUI Li-chun,WEI Lin,et al.Effect of Concurrent Chemoradiotherapy and Fuzheng Lung Cancer Recipe on Locally Advanced Non-Small Cell Lung Cancer[J].Journal of Medical Information,2019,32(23):166.[doi:10.3969/j.issn.1006-1959.2019.24.061]
[3]刘志坚,刘海燕,宿抱玉.阿帕替尼联合多西他赛治疗晚期非小细胞肺癌疗效和安全性的Meta分析[J].医学信息,2021,34(07):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]
　LIU Zhi-jian,LIU Hai-yan,SU Bao-yu.Meta-analysis of the Efficacy and Safety of Apatinib Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2021,34(23):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]
[4]石少庆.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果[J].医学信息,2023,36(01):152.[doi:10.3969/j.issn.1006-1959.2023.01.032]
　SHI Shao-qing.Clinical Effect of Apatinib Mesylate Tablets in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2023,36(23):152.[doi:10.3969/j.issn.1006-1959.2023.01.032]
[5]史建强,胡 云.扶正解毒汤辅助克唑替尼对晚期非小细胞肺癌患者临床疗效及对血清肿瘤标志物的影响[J].医学信息,2023,36(16):137.[doi:10.3969/j.issn.1006-1959.2023.16.027]
　SHI Jian-qiang,HU Yun.Clinical Efficacy of Fuzheng Jiedu Decoction Combined with Crizotinib in the Treatment of Patients with Advanced Non-small Cell Lung Cancer and its Effect on Serum Tumor Markers[J].Journal of Medical Information,2023,36(23):137.[doi:10.3969/j.issn.1006-1959.2023.16.027]

更新日期/Last Update: 1900-01-01